Cancer drug trial pulled before it even started

NCT ID NCT04372641

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This was a phase I trial testing a new drug called CB-5339 in people with advanced solid tumors or lymphomas. The drug was designed to block certain enzymes that cancer cells need to grow. However, the study was withdrawn before enrolling any participants, so no results or safety data were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CB-5339 (a p97 inhibitor taken by mouth)

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INDOLENT NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma cancer indolent B-cell non-Hodgkin lymphoma metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGGRESSIVE NON-HODGKIN LYMPHOMA INDOLENT NON-HODGKIN LYMPHOMA LOCALLY ADVANCED MALIGNANT SOLID NEOPLASM METASTATIC MALIGNANT SOLID NEOPLASM

Contacts and locations

Show contact details

Locations

National Cancer Institute Developmental Therapeutics Clinic

Bethesda, Maryland, 20892, United States
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States